Valo Health Appoints Chris Anagnostopoulos Chief Causal AI Officer

Valo Health appointed Chris Anagnostopoulos as Chief Causal AI Officer, a newly created role focused on advancing its human causal biology platform for drug discovery. The appointment was announced April 14 in a press release.

Anagnostopoulos will lead efforts to translate large-scale, real-world human data into causal insights that inform how drugs are discovered and developed. The role formalizes causal AI as a dedicated function within Valo’s platform.

Valo’s system is built on longitudinal datasets spanning more than 20 million patients, including records collected over 20 to 30 years with linked genomic data. The company uses machine learning to identify patient subtypes and applies causal inference techniques to determine the biological drivers of disease.

These insights feed into Valo’s predictive chemistry platform, where potential therapies are developed based on human-validated targets. The approach is designed to refine how diseases are classified and identify intervention points earlier in the discovery process.

“The creation of this position and strategic appointment underscore the importance we place on human causal evidence as the foundation of drug discovery, and the opportunity we see for causal AI/ML tools to help solve the translational gap,” Brian Alexander, CEO of Valo Health, said in the announcement.

“Drug discovery is struggling with a widening clinical translation gap, which consistently drives low clinical trial success rates, despite a growing number of drug candidates,” Anagnostopoulos said. “Addressing this causal gap requires integrating human causal biology insights as early as possible in drug discovery.”

Anagnostopoulos joins from QuantumBlack, part of McKinsey & Company, where he led AI innovation efforts in life sciences and co-founded the firm’s Scientific AI service line. His experience spans academia, consulting, and industry, including roles at Improbable and Imperial College London.

Valo appointed Karin Conde-Knape as Chief Scientific Officer in February, adding to its scientific leadership ahead of the new AI-focused role.